

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



To
BSE LIMITED
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

06th August 2025

Dear Sir/Madam

Subject: Unaudited Financial Results for the quarter ended 30th June 2025

Ref: BSE Scrip ID: CHEMCRUX

BSE Scrip Code: 540395

We would like to inform that the Board of Directors in its meeting held today i.e., 06th August 2025 inter alia, considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June 2025 as recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June 2025.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.30 A.M. and concluded at 02:25 P.M.

Thanking you

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal
Company Secretary & Compliance Officer

Factory

4712-14, GIDC, Road South - 10, Ankleshwar - 393002 (Gujarat) India.
Ph.: +91 2646 221427, 239737 | Email : sanjay@chemcrux.com

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Chemcrux Enterprises Limited** ('The Company') for the **quarter ended 30th June 2025**, read together with the Notes thereon ('the Statement'), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.
Chartered Accountants
FRN: 106928W

CA Harin Parikh

Partner

M.No. 107606

UDIN: 25107606BMOJEF5442

Place: Vadodara

Date: 06th August, 2025



CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007
 UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025

(All amounts are in INR lacs, unless otherwise stated)

	Particulars	Quarter Ended			Year ended
		30-06-2025 Unaudited	31-03-2025 Audited	30-06-2024 Unaudited	31-03-2025 Audited
I.	Revenue from operations	1,674.74	1,596.56	1,710.85	7,025.39
II.	Other income	60.70	27.74	38.77	152.96
III.	Total Income (I+II)	1,735.44	1,624.30	1,749.63	7,178.35
IV.	Expenses:				
	Cost of materials consumed	552.72	733.32	697.97	3,042.21
	Purchase of Traded Goods		-		-
	Changes in inventories of finished goods, by-products and work in progress	325.80	(187.64)	48.43	(236.26)
	Employee benefits expense	201.99	218.59	205.34	852.68
	Finance costs	52.41	58.29	13.16	163.84
	Depreciation and amortization expense	94.66	91.46	56.03	313.06
	Other expenses	434.79	637.47	552.58	2,460.01
	Total expenses (IV)	1,662.38	1,551.50	1,573.52	6,595.54
V.	Profit Before Tax	73.06	72.79	176.11	582.81
VIII.	Tax expense :				
	Current tax	1.42	2.66	45.30	75.00
	Deferred tax	13.19	22.62	6.99	90.06
	Income tax relating to earlier years	-	0.07	-	(1.11)
		14.61	25.35	52.29	163.96
IX.	Profit for the period	58.45	47.45	123.82	418.86
X	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Defined Benefit Plan	(13.06)	18.88	13.17	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.29)	4.75	3.31	6.59
	(iii) Items that will be reclassified to profit or loss				
	-Fair Value Gain on Investments	40.21	39.91	35.93	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	10.12	10.04	9.04	31.95
	Total other comprehensive income, net of tax	20.32	43.99	36.74	114.57
XI.	Total comprehensive income for the period	78.76	91.44	160.56	533.42
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)				
	- Basic (Rs.)	0.39	0.32	0.84	2.83
	- Diluted (Rs.)	0.39	0.32	0.84	2.83



Notes to Standalone Financial Results :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 06th August, 2025.
- 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 4 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board
Chemcrux Enterprises Limited**


Sanjay Marathe
Managing Director
DIN : 01316388



Place : Vadodara
Date : 06th August, 2025

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED FINANCIAL RESULTS

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Chemcrux Enterprises Limited** ("the Holding Company") and its Subsidiary ("Kalichem Private Limited") (the Holding Company and its Subsidiary together referred to as "the Group") for the **quarter ended 30th June 2025**, read together with the Notes thereon ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") as amended.

This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

The Statement includes the results of M/s. Kalichem Private Limited (Subsidiary)

Based on our review conducted and procedures performed as stated above, including the limited review of the unaudited financial results of the subsidiary company performed by us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Matters

- a) The Holding Company initially held 50% stake in Kalichem Private Limited making it a Joint Venture. The Holding Company acquired balance 50% stake in Kalichem Private Limited from the co-venturer M/s. Kalintis Healhcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of the Holding Company from that date.

Consequently, the Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2025, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations.

The figures relating to the quarter ended 30th June, 2024, quarter ended 31st March, 2025 and the year ended 31st March, 2025 appearing in the Statement are in accordance with the above.

- b) The Statement includes the figures relating to quarter ended 30th June, 2024 for which the financial results of M/s. Kalichem Private Limited were reviewed by other auditors whose review reports have been furnished to us. At that time M/s. Kalichem Private Limited was a Joint Venture and Consolidated under the Equity Method. Our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of Kalichem Private Limited for the Quarter ended 30th June, 2024 was based solely on the report of the other auditor and the procedures performed by us as stated above.

Our Conclusion on the Statement is not modified in respect of the above Other Matters.

For Naresh & Co
Chartered Accountants
FRN: 106928W


CA Harin Parikh
Partner

M.No. 107606

UDIN: 25107606BMOJEG2690

Place: Vadodara

Date: 06th August, 2025



CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025

(All amounts are in INR Lacs, unless otherwise stated)

	Particulars	Quarter Ended			Year ended
		30-06-2025 Unaudited	31-03-2025 Audited	30-06-2024 Unaudited	31-03-2025 Audited
I.	Revenue from operations	1,650.35	1,572.16	1,710.85	7,000.99
II.	Other income	44.07	23.52	38.77	148.74
III.	Total Income (I+II)	1,694.43	1,595.68	1,749.63	7,149.73
IV.	Expenses:				
	Cost of materials consumed	472.02	669.64	697.97	2,978.53
	Purchase of Traded Goods		-	-	-
	Changes in inventories of finished goods, by-products and work in progress	325.80	(187.64)	48.43	(236.26)
	Employee benefits expense	213.11	222.35	205.34	856.44
	Finance costs	85.81	69.00	13.16	174.55
	Depreciation and amortization expense	117.69	98.96	56.03	320.56
	Other expenses	476.90	656.84	552.58	2,479.38
V.	Total expenses (IV)	1,691.33	1,529.15	1,573.52	6,573.19
VI.	Profit Before Share in profit of Joint Venture (III-IV)	3.09	66.52	176.11	576.54
VII.	Share in Profit/(Loss) of Joint Venture (Net of Tax)		-	-	(0.50)
VIII.	Profit Before Tax	3.09	66.52	176.11	576.04
IX.	Tax expense :				
	Current tax	1.42	2.66	45.30	75.00
	Deferred tax	(7.59)	43.41	6.99	110.85
	Income tax relating to earlier years	-	0.07	-	(1.11)
		(6.17)	46.13	52.29	184.74
X.	Profit for the period	9.27	20.39	123.82	391.30
XI.	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Defined Benefit Plan	(13.06)	18.88	13.17	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.29)	4.75	3.31	6.59
	(iii) Items that will be reclassified to profit or loss				
	-Fair Value Gain on Investments	40.21	39.91	35.93	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	10.12	10.04	9.04	31.95
	Total other comprehensive income, net of tax	20.32	43.99	36.74	114.57
XII.	Total comprehensive income for the period	29.58	64.39	160.56	505.87
XIII.	Earnings per equity share (Nominal value per share Rs. 10/-)				
	- Basic (Rs.)	0.06	0.14	0.84	2.64
	- Diluted (Rs.)	0.06	0.14	0.84	2.64



Notes to Consolidated Financial Results :

- 1 List of Entities Consolidated included in the


Kalichem Private Limited

Joint Venture till 26.02.2025

Wholly-Owned Subsidiary from 27.02.2025

- 2 The above consolidated financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The above consolidated financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 06th August, 2025
- 4 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of in AS 108, on Operating Segment, constitute a single operating segment.
- 5 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board
Chemcrux Enterprises Limited**



**Sanjay Marathe
Managing Director
DIN : 01316388**



**Place : Vadodara
Date : 06th August, 2025**